Trastuzumab Recruiting Phase 2 Trials for Prostate Cancer / Cervical Carcinoma / Gliomas / Recurrent Colorectal Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Breast Carcinoma / Refractory Malignant Solid Neoplasm / Recurrent Uterine Corpus Carcinoma / Recurrent Malignant Solid Neoplasm / Gastric Carcinoma / Recurrent Bladder Carcinoma / Ovarian Carcinoma / Lung, Carcinoma / Recurrent Skin Carcinoma / Recurrent Colon Carcinoma / Refractory Plasma Cell Myeloma / Recurrent Liver Carcinoma / Recurrent Esophageal Carcinoma / Refractory Lymphomas / Head and Neck Carcinoma / Carcinoma, Colorectal / Recurrent Thyroid Gland Carcinoma / Recurrent Plasma Cell Myeloma / Endometrial Carcinoma / Recurrent Melanoma / Recurrent Head and Neck Carcinoma / Carcinoma, Pancreatic / Recurrent Lymphoma / Uterine Corpus Cancer / Plasma Cell Myeloma / Recurrent Solid Neoplasm / Recurrent Rectal Carcinoma / Thyroid Gland Carcinoma / Rectal Carcinoma / Carcinoma, Breast / Liver and Intrahepatic Bile Duct Carcinoma / Refractory Malignant Neoplasm / Advanced Malignant Solid Neoplasm / Recurrent Gliomas / Recurrent Pancreatic Carcinoma / Esophageal Carcinoma / Recurrent Cervical Carcinoma / Renal Carcinoma / Colon Carcinoma / Recurrent Prostate Carcinoma / Bladder Carcinoma / Malignant Uterine Neoplasm / Skin Carcinoma / Recurrent Lung Carcinoma / Solid Neoplasms / Advanced Malignant Neoplasm / Melanoma / Malignant Lymphomas / Recurrent Gastric Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02465060Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02436993Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab